Nephro Care

When is the next results date for Nephro Care?

No Upcoming Board Meetings

Has Nephro Care declared dividend?

No Dividend History Available

What is the technical trend for Nephro Care?

As of May 22, 2025, Nephro Care's trend is mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, with the stock underperforming the Sensex by -27.72% year-to-date.

As of 22 May 2025, the technical trend for Nephro Care has changed from sideways to mildly bearish. The daily moving averages indicate a bearish stance, while the weekly MACD is mildly bullish, suggesting mixed signals. The weekly Bollinger Bands and KST are both bearish, reinforcing the negative outlook. Additionally, the stock has underperformed the Sensex significantly year-to-date, with a return of -27.72% compared to the Sensex's 6.17%. Overall, the current stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands.

Who are the peers of the Nephro Care?

Nephro Care's peers include Aprameya Enginee, Unihealth Hosp, KHFM Hospitality, Maitreya Medica, Vaidya Sane, Lotus Eye Hospital, Aashka Hospitals, Asarfi Hospital, Abate As Indust, and Fortis Malar. Nephro Care has excellent management and growth ratings but a low 1-year return of -46.62%, significantly lower than its peers.

Peers: The peers of Nephro Care are Aprameya Enginee, Unihealth Hosp, KHFM Hospitality, Maitreya Medica., Vaidya Sane, Lotus Eye Hospit, Aashka Hospitals, Asarfi Hospital, Abate As Indust, and Fortis Malar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aprameya Enginee and Nephro Care, while Good management risk is found at Unihealth Hosp and Asarfi Hospital. Average management risk is present at KHFM Hospitality, Maitreya Medica., and Lotus Eye Hospit, whereas Below Average management risk is seen at Vaidya Sane and Aashka Hospitals. The rest have varying ratings, with Abate As Indust not qualifying. In terms of growth, Excellent growth is noted at Aprameya Enginee and Nephro Care, Good growth at Unihealth Hosp and Vaidya Sane, while Average growth is seen at KHFM Hospitality and the rest. Below Average growth is observed at Maitreya Medica., Lotus Eye Hospit, Aashka Hospitals, and Asarfi Hospital. Capital Structure ratings show Good at Nephro Care, Maitreya Medica., and Asarfi Hospital, Below Average at Aprameya Enginee, Unihealth Hosp, KHFM Hospitality, and Aashka Hospitals, while the rest have varying ratings.<BR><BR>Return Snapshot: Maitreya Medica. has the highest 1-year return at 119.67%, while Nephro Care has the lowest at -46.62%. Nephro Care's 1-year return is significantly lower than all peers. Additionally, KHFM Hospitality, Maitreya Medica., and Fortis Malar have negative six-month returns.

What does Nephro Care do?

Nephro Care India Ltd is a micro-cap company in the hospital industry, incorporated in 2014 and recently converted to a public limited company. It has a market cap of INR 223 Cr, with no recent revenue or profit data available.

Overview: <BR>Nephro Care India Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Nephro Care India Limited was incorporated on July 08, 2014, as a Private Limited Company and later converted into a Public Limited Company. The name was changed to Nephro Care India Limited, with a fresh Certificate of Incorporation issued on March 5, 2024. Revenue and profit data are not available for any recent quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 223 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 61.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 24.23% <BR>Price-to-Book: 14.41 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the top shareholders of the Nephro Care?

The top shareholder of Nephro Care is Pratim Sengupta, holding 60.71%, with individual investors owning 27.07% and 13 foreign institutional investors holding 3.5%. The highest public shareholder is Rohan Vinay Pai at 2.24%.

The top shareholders of Nephro Care include Pratim Sengupta, who is the promoter with the highest holding at 60.71%. The company has no pledged promoter holdings, and individual investors collectively hold 27.07% of the shares. Additionally, there are 13 foreign institutional investors (FIIs) that hold 3.5% of the company. The highest public shareholder is Rohan Vinay Pai, with a holding of 2.24%.

How big is Nephro Care?

As of 24th July, Nephro Care India Ltd has a market capitalization of 230.00 Cr, classified as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 15.03 Cr and Total Assets of 20.88 Cr.

As of 24th July, <BR><BR>Market Cap: Nephro Care India Ltd has a market capitalization of 230.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 15.03 Cr and Total Assets totaling 20.88 Cr.

Is Nephro Care overvalued or undervalued?

As of September 11, 2025, Nephro Care is considered expensive with a PE ratio of 74.28 and remains overvalued compared to peers, having underperformed the Sensex with a return of -35.06% over the past year.

As of 11 September 2025, Nephro Care's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its current financial metrics. The PE ratio stands at 74.28, the Price to Book Value is 5.06, and the EV to EBITDA ratio is 42.54, all of which are significantly higher than the industry averages.<BR><BR>In comparison to its peers, Nephro Care's valuation appears less favorable. For instance, Max Healthcare is categorized as very expensive with a PE ratio of 95.01, while Apollo Hospitals, considered fairly valued, has a PE ratio of 72.1. Despite this, Nephro Care's high valuation ratios suggest that it is overvalued relative to its peers. The company's stock has underperformed against the Sensex, particularly over the past year, with a return of -35.06% compared to the Sensex's modest gain of 0.35%.

How has been the historical performance of Nephro Care?

Nephro Care has experienced significant growth from March 2022 to March 2025, with net sales increasing from 3.42 Cr to 46.03 Cr, and total assets rising to 68.28 Cr. Despite fluctuations in profit metrics, the company shows a strong upward trend in financial performance and operational scaling.

Answer:<BR>The historical performance of Nephro Care shows significant growth over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Nephro Care's net sales have increased dramatically from 3.42 Cr in March 2022 to 46.03 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 3.42 Cr in March 2022 to 46.03 Cr in March 2025. The company's total expenditure also grew, reaching 40.16 Cr in March 2025 from just 3.30 Cr in March 2022. Operating profit, excluding other income, peaked at 5.87 Cr in March 2025, although it was slightly lower than the previous year's 6.47 Cr. Profit before tax showed fluctuations, with a high of 6.22 Cr in March 2024 but dropping to 4.83 Cr in March 2025. Profit after tax reached 3.64 Cr in March 2025, down from 4.50 Cr in March 2024, yet still a significant improvement from the loss of 0.01 Cr in March 2022. The company's total assets surged to 68.28 Cr in March 2025 from 4.63 Cr in March 2022, while total liabilities also increased to 68.28 Cr in March 2025, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved to 7.00 Cr in March 2025, and the closing cash and cash equivalents rose to 4.00 Cr, showcasing a positive cash position. Overall, Nephro Care's financial metrics indicate robust growth and operational scaling over the past few years.

Which are the latest news on Nephro Care?

Why is Nephro Care India Ltd falling/rising?

As of 03-June, Nephro Care India Ltd's stock price is rising to 71.65, up 4.07%, due to strong sector outperformance and increased investor participation. However, it has a year-to-date decline of 35.16% and is trading below its moving averages, indicating longer-term challenges.

As of 03-June, Nephro Care India Ltd's stock price is rising, currently at 71.65, reflecting an increase of 2.8 or 4.07%. This rise can be attributed to a notable outperformance against its sector, exceeding sector performance by 2.5%. Additionally, there has been a significant increase in investor participation, with delivery volume on June 2 rising by 96.67% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>However, it is important to note that despite the current rise, the stock has been underperforming over longer periods, with a year-to-date decline of 35.16% and a one-year drop of 46.65%. Furthermore, the stock is trading below its moving averages across various time frames, which suggests ongoing challenges. Nonetheless, the immediate increase in price today is primarily driven by increased trading activity and sector outperformance.